MD Anderson Cancer Center spinout OncoResponse has added $40.6m to its coffers thanks to series C investors including Arch Venture Partners.

OncoResponse, a US-based immunotherapy spinout of University of Texas MD Anderson Cancer Center, picked up $40.6m in a series C round today led by members of asset manager Magnetar Group.
Arch Venture Partners, Yonjin Venture, Bering Capital, RiverVest Venture Partners, Qatar Investment Authority (QIA), Redmile Group, Canaan Partners and 3B Future Health Fund (Helsinn Investment Fund), a vehicle for cancer drug developer Helsinn Group.
OncoResponse is developing antibodies intended to harness the body’s immune system to combat specific…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in